An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir-grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study).

Fiche publication

Date publication

janvier 2023

Journal

Health science reports

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre

Tous les auteurs :
Bronowicki JP, Miailhes P, Hanslik B, Ouzan D, Larrey D, Riachi G, Truchi R, Jouannaud V, Pospait D, Abergel A, Causse X, Perot S, Skrzypski J, De Hautecloque A, Spampinato A, Mariot P, Sogni P,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36479389

Résumé

The efficacy and safety profiles of elbasvir-grazoprevir (EBR/GZR) has been established in more than 10 clinical trials. However, the characteristics of patients treated in routine clinical practice may differ. The present study was therefore designed to assess the real-life effectiveness of EBR/GZR therapy in the general population and among subgroups with a high hepatitis C virus (HCV) prevalence in France.